Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
IPhEB Russia
Not Confirmed
Contact SupplierIPhEB Russia
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content
NEWS #PharmaBuzz
09 Jan 2025
// PRESS RELEASE
09 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/poseida-therapeutics-highlights-positive-interim-phase-1-results-for-p-bcma-allo1-and-preclinical-data-for-dual-car-t-p-cd19cd20-allo1-at-the-66th-american-society-of-hematology-ash-annual-meeting-302325606.html
09 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/09/2994099/0/en/Roche-commences-tender-offer-for-all-shares-of-Poseida-Therapeutics-Inc-for-9-00-per-share-in-cash-plus-a-non-tradeable-contingent-value-right-for-up-to-4-00-per-share-in-cash.html
26 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/26/2987189/0/en/Roche-enters-into-a-definitive-agreement-to-acquire-Poseida-Therapeutics-including-cell-therapy-candidates-and-related-platform-technologies.html
07 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2024-302299335.html
24 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-new-preclinical-data-supporting-non-viral-gene-editing-with-p-klkb1-101-for-the-treatment-of-hereditary-angioedema-302285382.html
Drugs in Development
Details:
P-CD19CD20-ALLO1 Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Sclerosis.
Lead Product(s): P-CD19CD20-ALLO1 Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Recipient: Genentech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2025
Lead Product(s) : P-CD19CD20-ALLO1 Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
P-CD19CD20-ALLO1 Safety, Tolerability, CK and PD In MS Participants
Details : P-CD19CD20-ALLO1 Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 06, 2025
Details:
The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: F. Hoffmann-La Roche
Deal Size: $1,500.0 million Upfront Cash: $1,500.0 million
Deal Type: Acquisition January 08, 2025
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Roche to Complete $1.5 Billion Acquisition of U.S. Biopharma Company Poseida
Details : The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $1,500.0 million
January 08, 2025
Details:
The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: F. Hoffmann-La Roche
Deal Size: $1,500.0 million Upfront Cash: $1,500.0 million
Deal Type: Acquisition November 26, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Roche Acquires Poseida for Cell Therapy Candidates and Platform Technologies
Details : The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $1,500.0 million
November 26, 2024
Details:
P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Poseida Reports Positive Interim Results For CAR-T Therapy in Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 27, 2024
Details:
P-BCMA-ALLO1 is a RMAT designated novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2024
Poseida Wins RMAT Designation from FDA for Multiple Myeloma Therapy P-BCMA-ALLO1
Details : P-BCMA-ALLO1 is a RMAT designated novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 16, 2024
Details:
Poseida and Xyphos will combine their technologies to develop a CAR-T construct targeting solid tumors, creating two convertibleCAR® product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Xyphos Biosciences
Deal Size: $600.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration May 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Xyphos Biosciences
Deal Size : $600.0 million
Deal Type : Collaboration
Astellas and Poseida Enter Research Collaboration for Cell Therapies
Details : Poseida and Xyphos will combine their technologies to develop a CAR-T construct targeting solid tumors, creating two convertibleCAR® product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
May 01, 2024
Details:
P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Poseida Receives FDA Orphan Drug Designation for P-BCMA-ALLO1 in Multiple Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 13, 2024
Details:
P-CD19CD20-ALLO1 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Lead Product(s): P-CD19CD20-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Genentech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2023
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Details : P-CD19CD20-ALLO1 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 28, 2023
Details:
Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Lead Product(s): P-MUC1C-ALLO1,Rimiducid
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Astellas Pharma
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 07, 2023
Lead Product(s) : P-MUC1C-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Astellas Pharma
Deal Size : $50.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 07, 2023
Details:
P-CD19CD20-ALLO1 is a first allogeneic dual CAR-T cell therapy which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.
Lead Product(s): P-CD19CD20-ALLO1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 05, 2023
Lead Product(s) : P-CD19CD20-ALLO1
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : P-CD19CD20-ALLO1 is a first allogeneic dual CAR-T cell therapy which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Poseida Therapeutics, Inc is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Rimiducid bulk with DMF offered by Poseida Therapeutics, Inc
Share 
